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Background: Colorectal cancer (CRC) is the second most prevalent type of cancer in Europe. A single flexible
sigmoidoscopy (FS) screening at around the age of 60 years prevents about one-third of CRC cases. However, FS
screens only the distal colon, and thus mortality from proximal CRC is unaffected. Computed tomography colonography
(CTC) is a highly accurate examination that allows assessment of the entire colon. However, the benefit of CTC testing
as a CRC screening test is uncertain. We designed a randomized trial to compare participation rate, detection rates, and
costs between CTC (with computer-aided detection) and FS as primary tests for population-based screening.
Methods/Design: An invitation letter to participate in a randomized screening trial comparing CTC versus FS will be
mailed to a sample of 20,000 people aged 58 or 60 years, living in the Piedmont region and the Verona district of
Italy. Individuals with a history of CRC, adenomas, inflammatory bowel disease, or recent colonoscopy, or with two
first-degree relatives with CRC will be excluded from the study by their general practitioners. Individuals responding
positively to the invitation letter will be then randomized to the intervention group (CTC) or control group (FS), and
scheduled for the screening procedure. The primary outcome parameter of this part of the trial is the difference in
advanced neoplasia detection between the two screening tests. Secondary outcomes are cost-effectiveness analysis,
referral rates for colonoscopy induced by CTC versus FS, and the expected and perceived burden of the procedures.
To compare participation rates for CTC versus FS, 2,000 additional eligible subjects will be randomly assigned to
receive an invitation for screening with CTC or FS. In the CTC arm, non-responders will be offered fecal occult blood
test (FOBT) as alternative screening test, while in the FS arm, non-responders will receive an invitation letter to
undergo screening with either FOBT or CTC. Data on reasons for participation and non-participation will also be
collected.
Discussion: This study will provide reliable information concerning benefits and risks of the adoption of CTC as a
mass screening intervention in comparison with FS. The trial will also evaluate the role of computer-aided detection
in a screening setting.
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Colorectal cancer (CRC) is the second leading cause of
cancer-related death in Europe and the USA [1]. It is the
most frequently diagnosed cancer in Europe for both
genders combined, with more than 400,000 new cases
and more than 200,000 deaths in 2008 [1]. About 46,000
incident cases, 267,000 prevalent cases, and 16,000
deaths from CRC are estimated in Italy for the year 2005
[2]. The lifetime risk of CRC in western countries is
about 5%. Population screening in asymptomatic individ-
uals at average risk for CRC reduces mortality, both
through the detection of malignancies at earlier, more
treatable stages, and through the identification and re-
moval of adenomatous polyps (pre-cancerous lesions
that may evolve to CRC) [3-9]. In addition, given the in-
crease in the costs of CRC treatment, screening has ac-
tually become cost-saving [10]. There are several tests
currently available for screening in the general popula-
tion, including stool tests, such as variants of the fecal
occult blood test (FOBT), and structural examinations
such as flexible sigmoidoscopy (FS), colonoscopy, and
CT colonoscopy (CTC). Each screening strategy has its
advantages and drawbacks.
The simplest and best-evaluated available screening
method is the FOBT, which is relatively inexpensive and
non-invasive, but less accurate than structural examina-
tions. The guaiac-based FOBT (gFOBT) may reduce
cancer mortality by up to 20% if offered biennially
[4,5,11], and possibly more if offered annually [8]. The
newer immunochemical FOBT (iFOBT) is considered to
perform better than gFOBT in detecting advanced neo-
plasia [12]. The disadvantages of FOBT include its low
sensitivity for adenoma and the requirement for frequent
testing, which may limit compliance and thereby effect-
iveness. Furthermore, repeat testing leads to high posi-
tivity rates.
FS is an endoscopic procedure, in which the distal 40
to 60 cm of the colon is inspected. Total colonoscopy is
advised in cases of positive findings. FS is less invasive
than colonoscopy, and requires only a simple bowel
preparation of a single enema within 2 hours prior to
the procedure. Three European randomized control tri-
als (RCTs) on FS have been performed [9,13,14]. In the
UK, one-time screening with FS significantly reduced
the incidence of CRC (by 26%) and associated mortality
(by 36%) [13]. In Italy, an 18% reduction in incidence and
a non-significant 22% reduction in mortality were re-
ported [9], whereas in Norway, no benefit was observed
after 7 years of follow-up [15]. A disadvantage of FS is
that it does not examine the proximal colon, but distal
findings are used to select a higher-risk group for colon-
oscopy. Another consideration is that its sensitivity de-
pends on the varied experience of the examiners, that has
a major impact on the adequacy of mucosal inspection.Colonoscopy and CTC are structural examinations
allowing inspection of the complete colon, and enabling
early detection of advanced adenomas (that is,, aden-
omas ≥10 mm or with unfavorable histological features)
and CRC [16]. Although colonoscopy is the most com-
plete endoscopic procedure available for CRC screening
[17,18], direct evidence about its effectiveness, complica-
tions, and acceptability among individuals at average risk
of CRC is still not adequate to justify its use for popula-
tion screening [19]. Observational evidence suggests that
colonoscopy might not be as effective in the proximal
colon as in the other segments of the colon and rectum
[20,21]. Furthermore, colonoscopy capacity is a limiting
factor for its widespread use as a primary screening test.
CTC may represent a reasonable alternative for colon-
oscopy [16]. First, this technique has a very high sensi-
tivity for already-developed CRC (96%) [22]. Secondly,
results from a large study of asymptomatic average-risk
individuals published in 2003 showed the diagnostic per-
formance of CTC for clinically relevant polyps to be
equivalent to that of colonoscopy [23]. Results from the
largest screening study (over 2,500 participants) [24]
showed 90% sensitivity of CTC for polyps 10 mm or lar-
ger and 86% specificity; the positive and negative pre-
dictive values were 23% and 99%, respectively. Important
advantages of CTC over colonoscopy are its minimally
invasive nature (only a small-caliber flexible rectal cath-
eter is needed for colonic distension) and the use of lim-
ited bowel preparation [25,26]. The risk of complications
from CTC is extremely low, particularly in asymptom-
atic individuals [27-30]. CTC with limited bowel prepar-
ation has a lower burden and is preferred by patients
compared with CTC with full cathartic preparation
[31,32]. Potentially, the addition of CTC to CRC screening
options could have a marked effect on current low adher-
ence rates, likely in a cost-effective manner [33-35]. In-
deed, results from a recent trial [25] on the use of
colonoscopy versus CTC for population-based screening
for CRC showed that participation with CTC was substan-
tially higher than with colonoscopy, and thus led to similar
advanced neoplasia detection rates. Disadvantages of CTC
include the exposure of individuals to ionizing radiation.
However, the chances of radiation-induced malignancy
are considered very low, especially when a low-dose
protocol is used. Furthermore, screening with CTC re-
quires subsequent colonoscopy if lesions are detected. A
high referral rate to colonoscopy might increase examin-
ation costs. CTC displays the abdominal organs external
to the colon. The prevalence of extracolonic diseases re-
quiring further investigation is not negligible, occurring in
approximately 6% of the individuals in asymptomatic
average-risk populations [25,36]. It is generally agreed that
relevant extracolonic findings should be reported [37].
However, although the detection of relevant extracolonic
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costs associated with false-positive results and inconse-
quential findings may be substantial [39].
Data concerning the neoplasia yield and the accept-
ability of CTC compared with colonoscopy have been
recently reported from the CoCos trial [25], but no in-
formation is available concerning the performance of
CTC compared with the recommended screening tests,
namely, iFOBT and FS. In European countries where na-
tional screening programs are ongoing, national policy
makers would require comparative data concerning the
performance of CTC (as of any other new screening test)
assessed against existing strategies before considering
the introduction of this test as an available screen for
average-risk individuals. A RCT, the SAVE Trial, has re-
cently been designed and funded in Italy to compare
CTC and iFOBT in a screening setting [40].
We are currently conducting a multicenter RCT to
compare the performance of CTC and FS in the context
of the population-based screening programs offering FS
once in a person’s lifetime in the Piedmont region and
the province of Verona in Italy. These organized pro-
grams were started in 2004, targeting all men and
women, aged 58 years (in Piedmont region) or 60 years
(in Verona) who are at average risk of CRC. Individuals
who do not respond to the FS invitation are offered
iFOBT as alternative.
Several issues need however to be addressed before
the implementation of a program using CTC as a pri-
mary CRC screening test. First, the local availability and
expertise of radiologists may affect the feasibility of CTC
screening. The use of information technology (IT) infra-
structures may allow subjects to undergo CTC at their
nearest imaging center, while test interpretation could
take place at a centralized level, requiring a smaller
number of readers. Implementing telediagnosis should
thus ensure high reporting quality, provided that highly
qualified radiologists, certified to report CTC, are se-
lected. The local availability of radiological centers could
also favor greater participation of individuals in the
screening programs.
Secondly, it is widely recognized that the interpret-
ation of CTC is challenging, probably more so in a low-
prevalence population. The need to view a large number
of images to detect a small number of clinically signifi-
cant lesions, the subtle nature of many radiological
characteristics of colonic lesions, and radiologist fatigue or
distraction may lead to an undesirable rate of false-
negative findings [41,42]. Computer-aided detection
(CAD) has the potential to improve the cost-effectiveness
of CTC by increasing detection of clinically significant le-
sions and/or reducing reporting times [43]. CAD as a sec-
ond reader (that is, CAD is applied after a complete and
unaided assessment) has been shown to increase readingsensitivity, albeit at the cost of increasing reading times
[44-47]. This increase in reading times is generally un-
desirable if a large number of cases must be read sequen-
tially, as occurs for population screening. A potentially
more time-efficient paradigm is first-reader CAD, in
which the reader’s interpretation is restricted to CAD
prompts alone [48]. However, detection of colonic find-
ings typically not targeted by CAD systems, such as
masses or atypical lesions, poses challenges [49].
The limitation of CAD for mass detection provides
motivation for double-reading first-reader CAD (DR FR-
CAD paradigm in which first-reader CAD is followed by
a rapid two-dimensional review of unprompted areas of
the colon, searching for masses or larger lesions missed
by CAD [50]. The addition of the human component to
first-reader CAD as a rapid control for eventual CAD er-
rors may overcome the issues related to automatic de-
tection. We hypothesized that DR FR-CAD could play a
key role in CTC screening by improving detection sensi-
tivity compared with unassisted reading, and by shorten-
ing interpretation time (while maintaining equally high
sensitivity) compared with second-reader CAD. Thus we
performed two preliminary studies [50,51] to investigate
the feasibility of using DR FR-CAD as a possible reading
strategy for CTC screening and to compare the diagnos-
tic performance and time-efficiency with those of
second-reader CAD for CRC screening [51]. Participants
included in this preliminary study underwent limited
bowel preparation with fecal tagging, as the available evi-
dence showed that limited preparation was not associ-
ated with a decrease in the CTC diagnostic performance
compared with full-cathartic preparation [52].
This multicenter RCT, assessing an average-risk popu-
lation aged 58 to 60 years, will compare the detection
rates of advanced neoplasia (advanced adenoma and
CRC) of CT colonography and sigmoidoscopy, and the
participation rates for the two programs. The data from
our preliminary research have allowed us to define a
CTC screening protocol (adopting an organizational
model based on telediagnosis together with DR FR-CAD
for CTC interpretation). The cost-effectiveness of this
protocol will also be tested in the proposed RCT.
Methods/Design
Objectives
Primary objective
The primary objective is to compare the participation and
detection rate of CTC and FS for advanced neoplasia (that
is, CRC and advanced adenomas) in a population-based
screening program for CRC.
Secondary objectives
The secondary objectives are 1) to evaluate the cost-
effectiveness and feasibility of CTC as a screening method
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a result of CTC versus FS; 3) to evaluate the reasons for
participation and non-participation to the proposed
screening strategies; 4) to evaluate the rate of complica-
tions in each screening group; and 5) to compare the ex-
pected and perceived burden of FS and CTC.
Study population
Eligible subjects are being identified through the rosters
of general practitioners (GPs). The target population in-
cludes all patients aged 58 (in the Piedmont region,
Italy) or 60 years (in the Verona district, Italy) who are
listed in the rosters of a random sample of GPs. In both
locations, GPs are asked to exclude any individuals un-
able to give informed consent; those with a family (two
first-degree relatives) or personal history of CRC, colo-
rectal polyps, or inflammatory bowel disease; those who
underwent a colonoscopy within the previous 5 years or
a FOBT within the previous 2 years; and those with a
medical condition that would preclude benefit from
screening. GPs are also asked to sign the invitation let-
ters and the reminders.
Study design
We have designed a population-based multicenter RCT
with two arms, involving six hospitals located in the
Piedmont region of Italy and two hospitals in the district
of Verona, Italy. To reduce bias in tests comparison, the
RCT is structured in two parts: 1) study 1 is comparing
the detection of CTC for advanced neoplasia with that
of FS; and 2) study 2 is comparing the participation rateGeneral Practitioner
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In study 1, a sample of 20,000 subjects aged 58 or 60
years living, respectively, in the Piedmont region and
Verona district, and who are listed in GP rosters will be
sent an invitation letter to receive screening for CRC as
part of a research trial (Figure 1). Individuals who agree
to participate into the trial will be randomly allocated to
FS or CTC screening in a 1:1 ratio. Random assignment
will be performed in each center by the local coordinat-
ing unit using a computer-generated allocation algo-
rithm. Participants will be randomly assigned on an
individual basis. Non-responders or individuals who re-
fuse to enter the trial will be invited to the standard
screening program by letter 1 month after the invitation
to the trial.
For study 2, an additional 2,000 individuals aged 58
years living in Turin, Italy and who are listed in GP ros-
ters will be randomly assigned to receive an invitation
for screening with CTC or FS (Figure 2). In the FS arm,
non-responders will be randomized subsequently to re-
ceive an invitation for screening with CTC or FOBT at 6
months from the initial invitation. In the CTC arm, non-
responders will be offered FOBT as an alternative
screening test. Simple randomization will be performed
by personnel of the Center for Cancer Prevention (CPO)
in Piedmont, Turin, using a computer-generated alloca-
tion algorithm, with an allocation ratio of 1:1.s (GPs’)
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Figure 2 Design of the screening trial comparing participation rates between computed tomography colonoscopy (CTC) and flexible
sigmoidoscopy (FS) as primary colorectal cancer (CRC) screening tests.
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Similar to our previous CRC screening trials [9,53], a
specialized database will be used for the logistics of the
invitation procedures. All targeted individuals will be in-
vited to the study by mailed invitations.
In study 1, eligible individuals will be mailed a letter
from their GP informing them that a CRC screening trial
comparing CTC versus FS is being performed in their
district, along with an information leaflet that outlines
the objectives of the trial, gives a general description of
the trial procedures, and describes the screening tests,
their advantages, and possible risks. The mailing speci-
fies that participation in the trial requires agreeing to be
randomized to receive one of the two study screen tests.
Recipients will be asked to call the screening center if
they want to take part in the trial, and those who re-
spond positively will then be randomized to either CTC
or FS. The telephone operator will also give each indi-
vidual detailed information on bowel preparation. In the
FS arm, participants will be asked to visit their GP or
the screening center to obtain the required enema kit,
while in the CTC arm, individuals will be asked to visit
the screening center to obtain the required bowel prep-
aration. Non-responders and individuals who do not
agree to participate in the study will receive an invitation
letter to undergo standard screening 1 month after the
invitation to the trial.
Differently, in study 2, the invitation letters offer a
pre-booked appointment for one of the screening proce-
dures. The mailing includes a leaflet containing a brief
description of the screening procedure (CTC or FS, de-
pending on the invitation), and its possible advantagesand side effects. The leaflets are based on those used in
the regional screening program. Invitees will be asked to
confirm, change, or cancel their appointment. The bowel
preparation procedures are the same as in study 1. Non-
responders will be sent a mailed reminder 3 months
after the initial invitation. In the CTC arm, individuals
who do not respond to the reminder will be offered
FOBT test, in accordance with the current screening
procedure. In the FS arm, non-responders to the re-
minder will receive an invitation letter to be screened
with either FOBT or CTC. The invitation letter for
FOBT invites the subject to contact the GP or the
screening center to obtain the kit and the necessary in-
formation for performing the test.
Primary screening tests
FS
Bowel preparation will be limited to a single enema (133
ml of 22% sodium phosphate) self-administered at home
2 hours before the test. There will be no dietary restric-
tions recommended. Screening will be performed in hos-
pital endoscopy units by gastroenterologists. The FS will
be performed with the use of a 130 cm colonoscope.
Participants with adequate bowel preparation will
undergo the procedure; operators will advance the col-
onoscope beyond the sigmoid-descending colon junc-
tion. Although no medication (such as spasmolytic or
sedative drugs) will be offered to the participants, it can
be administered if the endoscopist thinks it is necessary.
All polyps smaller than 10 mm detected during the FS
will be removed immediately and sent for histologic
evaluation. Participants with polyps 10 mm or larger as
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two adenomas detected following the histological examin-
ation *as described below) will be referred for total colon-
oscopy. After the examination, the endoscopist will give
the subject a letter that explains the results of their FS.
The letter also specifies the date for colonoscopy if large
polyps are detected, or for receiving the histology results if
small polyps are excised during the examination.
CTC
Individuals will be placed on a low-residue diet starting
3 days before the examination. Bowel preparation con-
sists of administration of one sachet of a Macrogol
3350-based mild laxative (Movicol; Norgine, Milan,
Italy) at each of the three main meals, starting 3 days be-
fore the examination. Two hours before the examin-
ation, participants will drink a 70 ml solution of sodium
diatrizoate and meglumine diatrizoate (Gastrografin;
Bayer Schering Pharma, Milan, Italy) diluted in 500 ml
of water, followed by an additional 500 ml of water. Im-
mediately before scanning, a radiologist or a trained
nurse will introduce a flexible rectal catheter, and disten-
sion will be produced using an automatic carbon-
dioxide insufflator (PROTOCO2L, Bracco; EZEM, Lake
Success, NY, USA). n-Butyl-scopolamine will be admin-
istered in accordance with the usual practice of each
participating center. The following low-dose protocol
will be adopted: 120 kVp (140 kVp in obese patients
with body mass index >30 kg/m2); 50 mA (effective) or
less per second (without the use of any system for dose
modulation); a rotation time of 0.5 to 0.7 seconds; a sec-
tion thickness not greater than > 1.25 mm, and recon-
struction interval of 1.25 mm or less. The total effective
dose per study should be less than 4 mSv. Intravenous
contrast medium will not be used. The radiologists and
nurses involved in the study will previously have under-
gone a 1 day course on examination technique and qual-
ity assurance.
In the Piedmont region, CTC examinations will be
performed in six different hospitals (FPO – IRCCS,
Candiolo, Torino; AOU San Giovanni Battista, Torino;
AO Ordine Mauriziano di Torino, AO Città della Salute
e della Scienza, Torino; Ospedale di Borgomanero-
Veruno, Novara; ASL di Biella, Biella) equipped with at
least 16 slice scanners. CTC images will then be trans-
ferred to a centralized reading center for interpretation
through a regional information communications tech-
nology (ICT) network infrastructure, using standard un-
compressed Digital Imaging and Communications in
Medicine (DICOM) format. Conversely, in the Verona
district, examination interpretation will be performed at
the same hospitals where the examinations are per-
formed (Ospedale di Borgo Trento and Ospedale di San
Bonifacio; both Verona).For all screening sessions, image processing and in-
terpretation will be performed using a CTC work-
station with CAD software (CAD-COLON software
version 1.20; im3D, Turin, Italy) whose stand-alone
performance has been reported elsewhere [44]. CTC
data will be evaluated by a radiologist using a DR FR-
CAD reading paradigm as previously reported [50]. In
brief, the radiologist will examine two lists of CAD
prompts, generated from the prone and supine series
respectively, using both two-dimensional and three-
dimensional viewing. Each CAD lesion may be rejected
by the radiologist as a CAD false-positive finding, or
accepted as a suspicious abnormality. To avoid missing
large flat or unusual lesions, the first-reader CAD will
be followed by a rapid unassisted two-dimensional in-
terpretation, again supplemented by three-dimensional
viewing for problem-solving. The radiologists reporting
in the trial must have: 1) reported at least 300
colonoscopy-verified CTC studies; 2) attended a 3 day
hands-on CTC screening course; and 3) have obtained
a per-patient sensitivity and specificity of at least 90%
during a final examination, which consists of interpret-
ing 30 screening cases.
CTC lesions
Diminutive polyps (5 mm or smaller) will be ignored, as
their potential for malignancy is very low. For all lesions
6 mm or larger, data on malignant certainty (low, mod-
erate, or high), size, location, and morphology will be
documented. Lesion size will be measured on either
multiplanar reconstructions or three-dimensional im-
ages. Morphological features (sessile, pedunculated, or
flat) will be noted. Non-polypoid lesions will be defined
as those with a base at least twice as long as the height.
Lesion location will be described in term of the six seg-
ments of the colon: the rectum, sigmoid colon, descend-
ing colon, transverse colon, ascending colon, and cecum.
Polyps 6 mm or larger detected by CTC will be verified
using segmental unblinding colonoscopy. For each le-
sion, a true-positive CTC finding will be defined as a le-
sion of at least 6 mm that is found at CTC in the same
or adjacent segment of the colonoscopy, with the size
within 50% margin of error.
Extracolonic evaluation of the CT images will be per-
formed in conjunction with the indicated colorectal
evaluation, using standard review with soft-tissue win-
dow. Thus, there will not be active searching for extra-
colonic lesions. Specific notes will be made in all cases
in which extracolonic lesions are found. However, only
patients presenting with findings of greater potential
clinical importance (that is, grade E4 according to the
CT Colonography Reporting and Data System-C-RADS
classification [37] and aortic aneurysms ≥4 cm) will be
referred to further work-up.
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We will use an immunological latex agglutination test
(OC Sensor, Eiken, Tokyo, Japan), performed on a single
stool sample with no dietary restrictions imposed on the
participant, with the positivity cut-off set at 100 ng/ml.
All FOBT samples collected in each study location will
be shipped weekly to a single central laboratory and
processed (automated processing and reading) in ac-
cordance with the manufacturer’s instructions. Partici-
pants with a positive test will be contacted by the study
staff and offered an appointment date for a colonoscopy.
A standard response letter will be mailed to participants
with a negative result.
Complications
Any complications that arise during screening (CTC or
FS), or immediately afterward, will be reported in the
examination record. Complications of CTC or FS that
occur within 30 days after the procedure will be re-
corded through the linkage with hospital discharge re-
cords and mortality registers. All complications will be
detailed according to type, timing, severity, treatment,
and outcome. Information about subsequent complica-
tions will be collected through self-report telephone
questionnaire administered 1 month after the examin-
ation. In addition, we will search the regional hospital
discharge databases to check for any hospitalizations
possibly related to screening test complications.
Follow-up and management of polyps
FS
All participants will be informed about the results of
their examination on the day of the procedure. If any
small polyps (<10 mm) have been removed, histology as-
sessment of tissue samples will be used to provide a de-
finitive diagnosis and participants will be informed about
the results within 2 weeks. Colonoscopy will be offered
to any participants with advanced adenomas (that is, one
adenoma ≥ 10 mm, or high-grade dysplasia, or villous
component >20%), or with three or more adenomas of
any type. Participants with a negative FS result or with
hyperplastic polyps or ‘low-risk’ adenoma (that is, <2
tubular adenomas with low-grade dysplasia and smaller
than 10 mm) will not undergo further follow-up.
CTC
If CTC reveals at least one lesion of 6 mm (C-RADS
grade 2) or larger (C-RADS 3 to 4), the participant will
be contacted by telephone and invited to undergo colon-
oscopy [37]. Participants whose examintion is inad-
equate according to the reporting radiologist, either
because of poor bowel preparation, poor distension, or
presence of artifacts, will be invited by telephone to
undergo FS. Participants with no colonic lesions or withpolyps smaller than 6 mm at CTC will be classified as
negative, and informed of their result by regular mail.
This cohort of participants will be scheduled for invita-
tion to undergo a FOBT after 2 years. Participants with
relevant extracolonic findings (that is, grade E4 and aor-
tic aneurysms >4 cm) will be contacted by telephone
and invited to the radiology unit of their nearest partici-
pating center for further investigations [37]. Extracolonic
diseases that have already been diagnosed prior to CTC
will be excluded from further assessments.
FOBT
All participants with a negative FOBT test will receive a
letter notifying the result, and an indication to repeat
the test after 2 years. All participants with a positive
FOBT result will be invited by telephone to undergo
colonoscopy.
Second-level colonoscopy
Second-level colonoscopy will be performed at the endo-
scopic unit of each participating center, using 130 cm
colonoscope and air insufflation. Bowel preparation con-
sists of a low-fiber diet starting 3 days before the exam-
ination and by the oral intake of 2 liters of polyethylene
glycol solution (Moviprep; Norginey) followed by 2 liters
of clear liquids the afternoon before examination. No
standard protocol for sedation will be introduced. How-
ever, all centers will be required to discuss with the par-
ticipant the advantages and drawbacks of performing
sedated colonoscopy. Colonoscopy will be considered
complete if the cecum is visualized or, in the case of fail-
ure, if a subsequent colonoscopy performed within 6
months after the index one is able to reach the cecum.
The combined results of the two examinations will be
included in the analysis. All detected lesions will be
measured with open biopsy forceps and annotated ac-
cording to their size, macroscopic appearance (sessile,
pedunculated, non-polypoid, vegetating, stenosing), and
location (rectum, sigmoid, descending, transverse, as-
cending, cecum).
Pathology
Histology will be defined according to the Word Health
Organization criteria [54]. Advanced adenoma will be
defined as an adenoma with any of the following fea-
tures: size 10 mm or larger, high-grade dysplasia, or a
villous component of more than 20%. Cancer will be de-
fined as the invasion of malignant cells beyond the muscu-
laris mucosae. Participants with intramucosal carcinoma
or carcinoma in situ will be classified as having high-grade
dysplasia. Participants will be classified on the basis of
their most advanced lesion in order to determine the
prevalence of pathological features. Polyp size will be clas-
sified according to the diameter of the largest polyp; for
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either the endoscopist or pathologist.
Questionnaires
Acceptability of the screening tests
The efficiency of CRC screening depends upon partici-
pants accepting and being able to complete the recom-
mended procedures [55]. Therefore, we will investigate
several issues related to the proposed screening tests,
using questionnaires administrated at three time points
to all participants in the CTC and FS groups. First, a
short itemized questionnaire evaluating discomfort due
to bowel preparation for the procedure will be adminis-
tered immediately before CTC and FS. After completing
the procedure, a second questionnaire assessing discom-
fort, pain, and embarrassment experienced during the
procedure will be administered. A third questionnaire
investigating all aspect of the screening procedure will
be administered by telephone interview 1 month after
the examination.
Reasons for participation or non-participation
Evaluation of factors associated with participation or
non-participation in a new screening program is an es-
sential component of this project. To understand the
reasons for participation or non-participation, a struc-
tured questionnaire will be administered by telephone to
a sample of individuals (both attendees and non-
attendees) who were invited to the study 2. This will assess
demographic and socioeconomic status, self-reported
health status, beliefs about the benefit of screening, atti-
tude to having regular medical control, perception of CRC
risk, adoption of health-promoting behaviors (for ex-
ample, physical activity, smoking habits). Factors including
medical advice about CRC, knowing a close relative or
friend with CRC, and experience of previous examinations
for early CRC detection or for other preventive tests (for
example, mammography/PAP test for women, prostate
testing for men) will be evaluated. Included items are
drawn from an existing questionnaire [56]. Both attendees
and non-attendees will be asked to indicate their main
reason for accepting or refusing screening. Non-attendees
will be asked to indicate factors that might possibly induce
them to undergo screening in the future, and to answer
questions investigating their knowledge of aspects of the
screening process as described in the leaflet (for example,
bowel preparation, duration of examination).
Cost-effectiveness analysis
This trial includes a full economic evaluation to examine
the relative cost-effectiveness of CTC screening com-
pared with FS screening and with no screening. Cost-
effectiveness analysis will be evaluated by incorporating
the trial data into a previously validated screening model[33]. The advantage of this analysis is that we will collect
cost data prospectively as part of the present screening
trial, including the direct costs (related to provision of a
diagnostic screening service) and the private costs to
subjects of participation in the study, such as travel
costs, out-of-pocket expenses, and costs of productivity
loss. Direct costs will include cost of investigating the
CTC colorectal and extracolonic findings, and the costs
of screening-induced complications. In detail, the yearly
CTC cost will be determined by separately collecting
data relative to the following costs: 1) medical/non-med-
ical staff; 2) initial and maintenance costs for CTC and
colonoscopy equipment; 3) disposable material for CTC
and colonoscopy; 4) hospital furniture for CTC and col-
onoscopy; 5) histological analysis of colonoscopy-
detected lesions; 6) other costs (for example, investment
in IT). These yearly costs will therefore be divided by
the estimated number of CTC screenings to be per-
formed in 1 year, in order to calculate the cost of each
CTC screening test. The effect of CTC examination on
the quality of life (QOL) of the participants will be indir-
ectly estimated by the questionnaires assessing the degree
of satisfaction and anxiety, which will be administered
after CTC screening completion. It is beyond the scope of
this study to assess the QOL of any participants diagnosed
with cancer, because of the very small number of cancers
expected in each arm. Furthermore, the cost-effectiveness
analysis will take into account the effects on health-related
QOL (or health status) from the process of screening for
CRC, such as pain, physical discomfort, or feelings of
anxiety or emotional distress. This analysis may provide
important information for larger-scale CRC screening pro-
grams using CTC.
Ethics approval
Approval for the study has been granted by the local
Ethics Review Committee in each clinical site: Comitato
Etico dell'Azienda Ospedaliera Universitaria S. Luigi
Gonzaga di Orbassano; AO Città della Salute e della
Scienza di Torino; Comitato Etico Interaziendale AOU
‘Maggiore della Carità`,’ ASL Biella, ASL Novara, ASL
Vercelli, ASL VCO; Comitato Etico Regina Margherita-
Sant'Anna-Ordine Mauriziano; amd Comitato Etico della
Provincia di Verona.
Data analyses
The primary endpoint of the study 1, the detection rate
of the screening test, is defined as the proportion of
screened subjects with advanced neoplasia divided by
the total number of screened subjects. Advanced neopla-
sia comprises all cancers and advanced adenomas to-
gether. The most advanced detected lesion per screened
subject will be used to calculate the detection rate. The
overall prevalence of polyps of any histology will also be
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will be calculated, and all proportions will be reported
with 95% confidence interval (CI). Differences in propor-
tions between screening strategies will be calculated
using the χ2 test. Multivariate logistic regression models
with advanced neoplasia as a function of sex, center, and
screening test will be used to analyze the differences in
detection rate between screening tests. Odds ratio (OR)
and its 95% CI will be used as a measure of the associ-
ation between detection and the variables under evalu-
ation. As a secondary analysis, we will calculate referral
rate for each screening test, defined as the proportion of
screening tests referred for colonoscopy because of an
abnormal result. For the comparison topic, we will use
the number of diagnostic colonoscopies induced by each
screening test as a proxy for resource utilization and
costs.
The primary endpoint of study 2, the participation rate
for the screening test, is defined as the number of partic-
ipants undergoing the screening test relative to the total
number of invitees. The χ2 test will be used to test if the
CTC group achieves a statistically significant difference
in participation compared with the FS group. Multivari-
ate models will be fitted to the data, with participation
as a function of sex, screening test, and sociodemo-
graphic characteristics. All statistical tests will be two-
sided and considered statistically significant at P < 0.05.Sample size
Comparison with endpoint of screening detection (study 1)
Based on the data from the Screening Colon Retto
(SCORE3) trial [53], the overall prevalence of advanced
neoplasia (advanced adenomas and CRC) in the target
age range is assumed to be 5% at FS screening. By in-
cluding 5,000 participants in the study (2,500 in each
screening group), we will achieve a statistical power of
80% to detect a 2% difference in detection rate between
the FS and CTC groups (5% versus 7%), using the con-
ventional 5% (two-tailed) level of statistical significance.
Assuming an adherence to the study of about 25%, we
plan to invite 20,000 eligible individuals. This assump-
tion is based on data from the SCORE3 trial [53].Comparison with endpoint of adherence to screening
invitation (study 2)
We plan to invite 1,000 individuals for screening with
FS, under the assumption that 25% of those invited will
accept the invitation [53]. Another 1,000 individuals will
be invited for screening with CTC. Thus, it will be pos-
sible to detect as statistically significant an absolute dif-
ference in participation rates of more than 5% with a
one-tailed test, setting the value of the alpha error equal
to 5% (power = 80%).Discussion
FS is currently recommended for population screening
programs in Italy, and is used in several regions [57].
CTC is a possible alternative to FS. To date, prospective
data about the effectiveness (CRC incidence/mortality re-
duction) of CTC in comparison with FS for population-
based screening are lacking. Moreover, several issues
concerning CTC implementation as a mass screening pro-
gram deserve to be addressed: patient compliance with
CTC (implying reduced bowel preparation), radiologist
reading times, radiologic workload, organizational impact,
and economic costs. Randomized trials are clearly needed
to test this novel screening approach and develop infra-
structures capable of maximizing the advantages and min-
imizing the burden of CTC use in screening, favoring its
feasibility and cost-effectiveness.
In Europe, several RCTs on the use of CTC as a CRC
screening strategy have been implemented or are about to
be implemented [25,40]. In these studies, CTC is com-
pared with FOBT screening or colonoscopy as a first-level
test. Our results and those of the aforementioned studies
will provide national and regional health system author-
ities with crucial information and experience on the utility
of CTC technology in CRC screening programs.
This RCT is designed to compare the detection rate of
CTC for advanced neoplasia versus FS. Detection of ad-
vanced neoplasia (measured in each screening arm as
the detection rate of advanced neoplasia among all par-
ticipants) has been universally adopted as a crucial end-
point when validating CRC screening techniques [58].
One challenge of a trial that has detection as the primary
endpoint is that the outcome assessment can be system-
atically influenced by selection and/or confounding
biases. A RCT does not guarantee comparable groups,
because selection and confounding biases may arise as a
result of human interference in the recruitment proce-
dures. For example, participants who agree to receive
CTC may be systematically different from participants in
the FS arm because of medical or family histories or life-
style choices that may be associated with a different like-
lihood of colorectal adenomas at screening [59]. This
may lead to systematic differences in the presence of ad-
vanced neoplasia between the screening arms, affecting
the results of the study and their validity. Thus, we have
attempted to reduce this form of bias by using a design
in which only participants without strong preferences
for one screening test will be randomized to the screen-
ing arms. In fact, participation in the trial is restricted to
individuals who consent to randomization. Although this
approach avoids confounding and should allow scientif-
ically accurate conclusions about screening detection, it
also hinders recruitment, and precludes the possibility of
evaluating adhesion to CTC invitation in comparison
with that to FS. However, adhesion to screening
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a screening program. Consequentially, the evaluation of
participation in a screening program should be in place
before any program implementation has begun. To
achieve this objective, we designed a second RCT, in
which eligible individuals are randomized without consent
to receive one of the two screening tests. Furthermore,
this second trial makes it possible to collect data on rea-
sons for participation or non-participation. Understanding
the reasons behind participation and non-participation
can be of help in the development of interventions aimed
at increasing uptake of screening for CRC.
When comparing FS and CTC as CRC screening
strategies, an important issue needs to be considered.
FS-detected polyps 6 mm or smaller can be removed
immediately, whereas such lesions are usually ignored
during CTC screening. Because the long-term implica-
tions of removing diminutive polyps are unknown, long-
term follow-up of very large samples would be required
to estimate the protection of CTC screening against
death. To our knowledge, no such trials are planned or
ongoing. However, our study will provide indirect evi-
dence of the long-term benefit from CTC screening by
comparing the detection rates for CTC versus FS and
assuming long-term efficacy of FS screening consistent
with the results from the SCORE trial [9]. Of note, the
SCORE trial evaluated the protection for FS screening
over time in the same screening setting.
One more issue we kept in mind while planning the
trial is that overall costs of CTC screening could be af-
fected by uncritical reporting of extracolonic findings
[37]. Whether the visualization of extracolonic struc-
tures and potential pathology is a real benefit or a disad-
vantage is still under debate. On the one hand, CTC
may incidentally identify asymptomatic malignant dis-
eases or other clinically important conditions, thus pos-
sibly reducing mortality. On the other hand, CTC may
reveal numerous findings of no clinical relevance, which
could result in costly additional diagnostic examinations
with an overall negative impact on cost-effectiveness
[39]. However, in some cases, detection of relevant
extracolonic findings such as abdominal aortic aneu-
rysms (AAA) and extracolonic masses at an early stage
may be beneficial. According to one study, the net ef-
fect from detection of both AAAs and extracolonic
cancers appears to be positive in term of life-years
gained and overall cost-effectiveness [38]. Further-
more, cost-effectiveness analyses have also shown that
screening for AAA provides high clinical efficacy at a rela-
tively low cost [60]. Based on these considerations, we de-
cide to report and follow only potentially important
extracolonic findings such as abdominal and pelvic masses,
and AAA larger than 4 cm, which represent only a minor-
ity of all extracolonic findings. This study will provide newknowledge on this topic through a separate analysis of the
additional costs created by referring patients wtih import-
ant extracolonic findings for second-level tests.
In this trial, we are implementing a telediagnosis
model for CTC reading, which consists of performing
the examinations in different regional hospitals and
sending data via telematic infrastructures to a central
unit where the CTC examinations are interpreted by expe-
rienced radiologists. It is hoped that this organizational
model will ensure high diagnostic quality, as it enables
reporting to take place in a protected environment by a
board of dedicated radiologists with certified experience in
CTC. The use of a telediagnosis model may also favor ad-
herence to CTC invitation thanks to the local availability
of radiological centers that can perform examinations. A
comprehensive evaluation on cost-efficiency of a telediag-
nosis model for CRC screening by CTC will include all
these aspects.
In this trial, we are using the DR FR-CAD reading para-
digm. In our preliminary work, we showed that this new
reading modality is just as accurate as second reader
CAD, but is less time-consuming [51]. It is hoped that this
RCT will confirm the results of these preliminary findings.
In summary, this RCT will assess the efficacy of a CRC
prevention program with CTC as a mass screening strat-
egy in some regions of Italy, providing information about
adherence, detection rate, and costs of this test com-
pared with FS. In addition, the collection of data for
cost-effectiveness analysis as part of this RCT will help
to capture important aspects of CTC screening, such as
adverse effects on QOL, resource use, and indirect costs.
Thus, this trial will provide relevant information to
decision-makers who need to consider evidence of eco-
nomic value along with clinical efficacy when making
decisions on resource allocation.
Trial status
The trial started recruitment in December 2010. At the
time of writing, 2,000 participants had been enrolled in
the study overall.
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